Breyanzi (lisocabtagene maraleucel) / BMS - LARVOL DELTA

Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy. (PubMed, Curr Oncol) - "In a retrospective comparative analysis of clinical outcome, there were significant differences in CTLA4 A17hom vs. T17Ahet and T17hom carriers with four-year progression-free survival at 77%, 59%, and 30% (p = 0.019), four-year overall survival was 79%, 41%, and 33% (p = 0.049), the relapse rates were 20%, 37%, and 56% (p = 0.025), and the death rates 20%, 54%, and 52% (p = 0.049). CTLA4 rs231775 polymorphism may impact the treatment outcome in FMC63-anti-CD19 CAR-T cell therapy, with an association of the CTLA4 minor allele A17 to favorable treatment outcome."

IO biomarker • Journal • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CTLA4

New Immunotherapeutic Horizons in Richter's Transformation: Synergistic Approaches with Targeted Agents (SOHO 2025) - "BTK inhibitors, such as ibrutinib and zanubrutinib, have been shown to modulate immune function, reducing regulatory T-cell activity and altering cytokine profiles...Pembrolizumab and nivolumab achieved response rates of approximately 13% to 20%, with a median OS of less than 6 months...The landscape shifted with the RT1 trial, which evaluated the combination of tislelizumab, a PD-1 inhibitor, with zanubrutinib in 48 patients with RT...The MOLTO trial adopted a triplet strategy, combining atezolizumab, a PD-L1 inhibitor, with venetoclax and obinutuzumab...Support for combination strategies comes from a recent case series by Smith et al, in which six RT patients were treated with lisocabtagene maraleucel (liso-cel)...9,10 Given these encouraging results, epcoritamab is being tested in combination with venetoclax, R-CHOP, and other immune modulators...Other bispecific constructs under investigation include glofitamab and mosunetuzumab, each with distinct pharmacokinetic..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • HAVCR2 • LAG3 • NOTCH1 • PD-L2 • TP53

Relapsed/Refractory Indolent Lymphoma: Options Beyond Immunotherapy (SOHO 2025) - "Third-line immunotherapy-based strategies are now approved for the treatment of patients with multiple relapses, including the chimeric antigen receptor T-cell (CAR-T) constructs axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, as well as bispecific antibodies like the anti-CD20 × CD3 agents mosunetuzumab and epcoritamab...Obinutuzumab was chosen as the companion of zanubrutinib due to the high proportion of rituximab-refractory patients enrolled in the study and was administered in both arms up to 20 infusions...Loncastuximab with Rituximab In a population of 39 advanced-stage FL patients, including 20 cases of disease relapse within 24 months since frontline treatment (POD24), the combination of the two drugs in an outpatient fixed-duration regimen produced a complete response rate of 67% after 12 weeks on-therapy, which rose to 77% within 21 weeks...Compared with existing agents targeting Ikaros/Aiolos, such as lenalidomide, avadomide, and..."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CRBN • IKZF1

Debate: Progression on Covalent BTK Inhibitors — Change to Non-Covalent BTK Inhibitors (SOHO 2025) - "When venetoclax was evaluated following ibrutinib, 47% had del(17p), and 33% had TP53 mutations, with a median progression-free survival (PFS) of 24.7 months.(Jones et al., 2018) The poor outcomes in this population were further illustrated in the TRANSCEND-CLL study...Whether it is the combination with obinutuzumab, the complicated ramp-up schedule, or the requisite monitoring, the utilization of venetoclax has struggled to match the efficacy of the drug...We therefore eagerly await the results of the Bruin CLL-322 study, in which venetoclax and rituximab are compared with and without the addition of pirtobrutinib...Liso-cel struggled in the TRANSCEND CLL study because the acuity of patients enrolled in the study hampered the ability of the autologous chimeric antigen receptor T-cell (CART) product to demonstrate its full potential...While both pirtobrutinib and venetoclax represent treatment options for patients following treatment failure with covalent BTK inhibitors,..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Oncology • CD20 • TP53

Management of Mantle Cell Lymphoma in Patients Previously Treated with Covalent BTK Inhibitors (SOHO 2025) - "Noncovalent BTKis Noncovalent BTKis, such as pirtobrutinib, offer a promising option in the post-covalent BTKi setting, with clinically meaningful activity...8,9 Among available CAR T-cell therapies in this setting, axicabtagene ciloleucel (axi-cel) has demonstrated excellent long-term outcomes, while lisocabtagene maraleucel (liso-cel) — although with shorter available follow-up data — demonstrates lower rates of high-grade CAR T-cell therapy-related toxicities, including cytokine release syndrome (CRS) and immune effector-associated neurotoxicity syndrome (ICANS)...Bispecific antibodies, such as glofitimab and mosunetuzumab, have demonstrated promising activity in clinical trials, either alone or in combination with other agents, including the antibody-drug conjugate polatuzumab vedotin...However, CRS remains a potential issue with the use of bispecifics in MCL, although step-up dosing and the use of obinutuzumab pretreatment have been associated with reduced..."

Clinical • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CCND1 • CD20

Phase 2 study of the combination of lisocabtagene maraleucel, nivolumab, and ibrutinib in Richter's transformation - NCT05672173 (IWCLL 2025) - P2 | No abstract available

P2 data • Hematological Malignancies • Richter's Syndrome

Secondary Primary Malignancies (SPMs) in Patients Having Received CAR T-Cell Therapy: A Real-World Propensity-Matched Study Using the TriNetX Database (SOHO 2025) - "Tisagenlecleucel, lisocabtagene maraleucel, and axicabtagene ciloleucel are FDA-approved anti-CD19 CAR T-cell therapies...We used 1:1 propensity score matching to decrease the impact of confounding factors, including age, sex, gender, race, transplant status, history of nicotine dependance, alcohol use, radiation, and use of any of the following five carcinogenic agents: cyclophosphamide, carmustine, bendamustine, lomustine, and cisplatin... Patients having been administered anti-CD19 CAR T-cell therapies should be screened at regular intervals for development of MDS. More research and prolonged follow-up time is needed to comment on the relationship between CAR T-cell therapy and other SPMs."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Prostate Cancer • Solid Tumor

Therapy Sequencing in Relapsed/Refractory MCL (ICML 2025) - P1, P1/2, P2, P3 | "Although a direct comparison between them has only been performed for ibrutinib and temsirolimus [23], covalent BTK inhibitor (cBTKi) single agent therapy has been consolidated as the standard of care after first-line CIT. Moreover, to address cBTKi failure, two anti-CD19 CAR-T cell therapy products, brexucabtagene autoleucel [20, 21] and lisocabtagene maraleucel [22], and the first noncovalent BTKi, pirtobrutinib [19], have recently been approved...Liso-cel only FDA approved; CIT, chemoimmunotherapy options include BR, R-BAC, R-CHOP, R-DHAP or R-DHAOx, R-GEMOx, paliative options (avoid bendamustine pre-CART apheresis); pirtobrutinib, available after cBTKi failure in second-line (EMA) but third-line (FDA); RM, rituximab maintenance...Orelabrutinib [18] is licensed only in China...Of note, both acalabrutinib and zanubrutinib induce lower rates of atrial fibrillation, hypertension, and bleeding compared to ibrutinib in randomized studies..."

IO biomarker • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Oncology • PLCG2 • TP53

High-Risk MCL: Definition and Innovative Treatment Strategies (SOHO 2025) - "Pirtobrutinib, a non-covalent BTKi, demonstrates activity in patients with prior BTKi exposure, though less effective in this population compared to BTKi-naïve patients with complete response [CR] rates of 20% vs 35%, respectively...Glofitamab, a CD20 × CD3 BITE, appears more promising in patients with prior BTKi exposure, eliciting CR rates of 71%, a median duration of CR of 12.6 months, and median PFS of 8.6 months...ZUMA-2 evaluated brexucabtagene autoleucel in R/R high-risk MCL, while the TRANSCEND MCL cohort evaluated lisocabtagene maraleucel in a similar population of R/R MCL but also allowed for more prior lines of therapy and secondary central nervous system (CNS) disease (8% of patients)...Selected upfront chemotherapy-free trials for high-risk MCL patients Trial Regimen Outcome in overall population Outcomes in TP53- mutated or aberrant MCL Outcomes in other high-risk MCL TP53 mutations = 15% pts mPFS 39 mo High MIPI = 38% Outcomes inferior to overall..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Lymphoma • Mantle Cell Lymphoma • Oncology • KMT2D • NOTCH1 • NOTCH2 • ROR1 • SMARCA4

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation (ICML 2025) - P=N/A, P2, P3 | "BRUIN CLL-321 is a phase 3, registrational study that evaluated pirtobrutinib compared to the investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) [23]...Nemtabrutinib is now being evaluated in the registrational, phase 3 BELLWAVE-010 trial (NCT05947851) for patients with R/R CLL, comparing nemtabrutinib plus venetoclax to venetoclax plus rituximab...An ongoing, open-label, first-in-human phase 1/2 study is evaluating the BTK degrader BGB-16673 as monotherapy in patients with R/R CLL [27, 28]...NX-2127 is an investigational, first-in-class BTK degrader currently being evaluated in a phase 1 trial for patients with relapsed or refractory B-cell malignancies, CLL [29, 30]...NX-5948 is another investigational and more selective BTK degrader in an ongoing Phase 1a/1b clinical trial...This trial aims to establish lisaftoclax plus acalabrutinib as a potential alternative to venetoclax-based BTKi combination..."

IO biomarker • Acute Myelogenous Leukemia • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • Small Lymphocytic Lymphoma • BCL2L1 • TP53

Patients With Large B-Cell Lymphoma (LBCL) Who Achieve Complete Response With Lisocabtagene Maraleucel (liso-cel) Have Durable Remissions: Data From Real-World and Clinical Trial Settings (SOHO 2025) - P1, P2, P3 | "Patients with R/R LBCL who achieve CR after liso-cel experience durable remissions and long-term survival, with consistent results in both clinical trial and real-world settings."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Safety, Efficacy, and Length-of-Stay Analysis of Outpatient CAR-T Therapy in Non-Hodgkin Lymphoma Patients at a Community-Based Medical Center (SOHO 2025) - "Objectives: Assess the safety, tolerability, and outcomes of outpatient CAR-T therapy for non-Hodgkin lymphoma patients treated with axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), tisagenlecleucel (tisa-cel), or brexucabtagene autoleucel (brexu-cel) in a community setting...None received prophylactic dexamethasone or tocilizumab... Outpatient CAR-T therapy is feasible with comparable safety, efficacy, and improved cost effectiveness based on lower length of hospital stay. Larger prospective studies are warranted."

Clinical • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Nodal Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Cardiovascular Adverse Events Among Cancer Patients Receiving Chimeric Antigen Receptor T-Cell Therapy (SOHO 2025) - "Adult patients (≥18 years) who received one of the six FDA-approved CAR-T products (tisagenlecleucel, axicabtagene, brexucabtagene, lisocabtagene, idecabtagene, or ciltacabtagene) between years 2017-2024 were included, using relevant procedure codes. CAEs were observed in about 26% of CAR-T recipients within 3 months, with hypotension being the most common manifestation. Importantly, up to 6% of patients developed heart failure. These findings highlight the need for heightened cardiovascular monitoring, especially because hypotension may not always be attributable to CRS alone."

Adverse events • CAR T-Cell Therapy • Clinical • Diffuse Large B Cell Lymphoma • Oncology

New Targets and Drugs on the Horizon in Chronic Lymphocytic Leukemia (SOHO 2025) - P1, P1/2 | "12 Treatment planning for patients with " double refractory " CLL — CLL that is resistant to a covalent BTKi and venetoclax — is a relatively novel but emerging scenario in the clinic...Noncovalent (Reversible) BTK Inhibitors In the BRUIN-321 phase 3 randomized trial of pirtobrutinib monotherapy versus the control arm of the investigator's choice between idealisib plus rituximab or bendamustine plus rituximab, pirtobrutinib had improved PFS (14 vs 8.7 months, Hazard ratio [HR] 0.54, P = 0.0002) and a superior time to next treatment or death compared to the control arm (24 vs 10.9 months, HR 0.37, P < 0.0001)...Nemtabrutinib is another noncovalent BTKi under clinical investigation, demonstrating an overall response rate (ORR) of 36.4% in CLL patients in the phase 1 study (n = 22 patients)...23,24 Thus far, data for three orally administered BTK degraders — NX-2127, NX-5948 and BGB-16673 23–25— have been presented, and there are ongoing clinical..."

IO biomarker • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Leukemia • Lymphoma • Oncology • CD20 • PRKCB • PRKCH • ROR1

Optimizing Post-Chimeric Antigen Receptor (CAR) T-Cell Monitoring: Evidence Across Lisocabtagene Maraleucel (liso-cel) Pivotal Clinical Trials and Real-World Experience (SOHO 2025) - "Background: CAR T-cell therapies show remarkable efficacy in B-cell non-Hodgkin lymphoma. In lisocel pivotal trial and SOC settings, most CRS/ICANS occurred ≤2 weeks after infusion and were not severe. For the few patients with CRS/ICANS onset >D15, most events were low grade and resolved. Funding: Bristol Myers Squibb."

Clinical • Real-world • Real-world evidence • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center Do Not Impact Survival Outcomes of Patients With non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies (SOHO 2025) - "CAR T-cell products used included axi-cel, tisa-cel, liso-cel, brexu-cel (B-NHL) and ide-cel and cilta-cel (MM). In this single-center study, neighborhood disadvantage and DTC did not impact response or survival outcomes in patients with access to CAR T-cell therapies. However, patients from more disadvantaged neighborhoods had to travel farther. These findings highlight access disparities and support broader, multicenter studies to assess their impact on CAR-T delivery and outcomes."

CAR T-Cell Therapy • Clinical • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Holding and Bridging Therapy Selection in Relapsed/Refractory Aggressive B-Cell Lymphoma (SOHO 2025) - P3 | "This treatment approach was first available in the third- or later-line (3L+) setting, based on the results from single-arm trials — namely ZUMA-1 (axicabtagene ciloleucel [axi-cel]), JULIET (tisagenlecleucel [tisa-cel]), and TRANSCEND-NHL-001 (lisocabtagene maracelucel [liso-cel])...It is part of an approved regimen for R/R LBCL in second- or later-line treatments — namely the rituximab-bendamustine-polatuzumab (RBP) combination...23,24 Both loncastuximab and tafasitamab are approved for R/R LBCL patients, 25,26 and they share the same target as CAR T cells...Response to BT has a significant prognostic impact on the efficacy and toxicity of CAR T-cell therapy. Ongoing trials with radiotherapy and novel agents will shed light on their role in this setting."

IO biomarker • B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD4

Glycemic Outcomes Following CAR T-Cell Therapy: A Real-World Multicenter Analysis of Hemoglobin A1c Trends (SOHO 2025) - "CAR T-cell agents included axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, and ciltacabta-gene autoleucel. This real-world analysis suggests that approximately 1 in 10 patients may develop elevated HbA1c following CAR T-cell therapy, raising concern for treatment-associated glycemic disturbances. The observed patterns— particularly among younger and racially diverse subgroups— highlight the need for further investigation. While causality cannot be established from retrospective data alone, these findings underscore the importance of post-CAR T-cell therapy metabolic monitoring and support prospective studies to define risk factors and long-term outcomes."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hematological Malignancies • Oncology

Lisocabtagene Maraleucel in Relapsed or Refractory (R/R) Follicular Lymphoma (FL; TRANSCEND FL): Impact of Prior Lines of Therapy (LOT), Bendamustine Exposure, and Disease Progression ≤24 Months of Initial Systemic Therapy (POD24) (SOHO 2025) - "Background: We report subgroup analyses by number of prior LOTs, POD24 status, and prior bendamustine exposure in lisocel-treated patients from the FL cohort of TRANSCEND FL. Data support sustained clinical benefit and manageable safety of liso-cel in patients with R/R FL, regardless of POD24 and prior bendamustine, trending towards better outcomes in earlier LOTs. Funding: Celgene, a Bristol-Myers Squibb Company."

Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Comparative Effectiveness and Safety of Salvage Chemotherapy Regimens Versus Chimeric Antigen Receptor T-Cell Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bayesian Network Meta-Analysis (SOHO 2025) - "While many patients are cured with R-CHOP, a substantial number relapse or develop refractory disease, particularly after second-line treatment failure or ineligibility for autologous stem cell transplantation. CD19-directed CAR-T therapies offer superior clinical benefit compared with salvage chemotherapy in R/R DLBCL. Axi-cel provides strong disease control with higher toxicity, while tisa-cel and liso-cel offer more favorable safety profiles. These findings support CAR-T therapies as the preferred treatment in eligible patients and emphasize the need for personalized treatment strategies based on efficacy, toxicity, and patient factors."

CAR T-Cell Therapy • HEOR • Retrospective data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Best of Cell Therapy for Lymphoma: What We Learned in 2024 and 2025 (SOHO 2025) - P1/2, P2 | "Autologous CAR-T Therapy CD19 CAR-T New Regulatory Approvals In March 2024, the United States Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (lisocel) for relapsed/refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) after Bruton tyrosine kinase inhibitors (BTKis) and B-cell lymphoma 2 (BCL2) inhibitors, making it the first CAR-T approval in this disease...Long-Term Follow-up of Pivotal CD19 CAR-T Trials TRIAL (PRODUCT) LYMPHOMA SUBTYPE MEDIAN FU (MONTHS) ORR (%) CR (%) MEDIAN PFS (MONTHS) PFS (%) OS (%) NOTABLE SAFETY FINDINGS 64.6 90 75 (79% in FL cohort, 65% in MZL cohort) 62.2 53 (5 yr) 69 (5 yr) No new late signals ZUMA-5 (AXICEL) FL/MZL ( ≥ 3L) ELARA (TISA-CEL) FL ( ≥ 3L) 53 – * 69.1 53.3 50.2 (4 yr) 79.3 (4 yr) No new late signals; 6.2% secondary primary malignancies TRANSCEND FL (LISO-CEL) FL (2L+ high-risk/3L+) 29.5 – 30 95.7 – 97.1 94.2 – 95.7 NR 72.5 – 82.6 (2 yr) 88.2 –..."

IO biomarker • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Chronic Lymphocytic Leukemia • Follicular Lymphoma • Hodgkin Lymphoma • Indolent Lymphoma • Large B Cell Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Oncology • Peripheral T-cell Lymphoma • Small Lymphocytic Lymphoma • T Cell Non-Hodgkin Lymphoma • CD22 • CD5 • IL15 • TNFRSF8

Racial Disparities and Demographics in Recruitment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy: A Cross-Sectional Review (SOHO 2025) - "Background: Between 2017 and 2021, three chimeric antigen receptor (CAR) T-cell therapies (ie, axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel) gained approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after two or more prior lines of treatment. This cross-sectional analysis highlights racial and sex differences in clinical trial recruitment for CAR T-cell therapy in relapsed/refractory DLBCL compared with broader prevalence data for DLBCL. A lower proportion of African Americans are recruited to CAR-T trials in relapsed/refractory DLBCL compared with disease prevalence. There is also a male preponderance in trial recruitment compared with prevalence."

CAR T-Cell Therapy • Review • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma (SOHO 2025) - " We identified 239 patients (92% [n = 220] axicabtagene ciloleucel, 7% [n = 17] lisocabtagene maraleucel, and 1% [n = 2] tisagenlecleucel) with R/R LBCL. Baseline MTV is an independent prognostic biomarker for treatment efficacy in patients with R/R-LBCL receiving CAR-T. These findings support incorporating MTV into pretreatment risk stratification, warranting external validation in larger cohorts."

Biomarker • CAR T-Cell Therapy • IO biomarker • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Neurovascular/Stroke-Related Safety of the CAR T-Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Aggressive B Cell Lymphoma: A Systematic Review (SOHO 2025) - "Neurovascular events such as stroke and cerebral edema, though uncommon, are significant concerns in patients receiving CD19 CAR-T therapies for aggressive B-cell lymphoma. Recognition of overlapping symptoms with ICANS is essential for timely diagnosis and intervention. Further research is essential to mitigate these risks and improve patient outcomes."

CAR T-Cell Therapy • Clinical • Review • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • IL6

Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study (SOHO 2025) - P2 | "In patients with R/R MZL, lisocel demonstrated deep and durable responses with high 24-month survival rates. With a manageable safety profile, liso-cel is a potential treatment option for patients with R/R MZL. Funding: Celgene, a Bristol-Myers Squibb Company."

Clinical • P2 data • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Oncology • T Cell Non-Hodgkin Lymphoma